US 11998521
Use of an RXR agonist in treating drug resistant HER2+ cancers
granted A61KA61K2039/505A61K31/198
Quick answer
US patent 11998521 (Use of an RXR agonist in treating drug resistant HER2+ cancers) held by The Board of Regents of the University of Texas System expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 23
- CPC classes
- A61K, A61K2039/505, A61K31/198, A61K31/215, A61K31/216